3C Therapeutics
1 known investors
3C Therapeutics develops therapeutics using targeted protein degradation, centered on a proprietary modular Degrader-Antibody Conjugate (DAC) platform (TriCore) that delivers intracellular protein degraders via monoclonal antibodies. The company focuses on drug discovery for previously inaccessible targets through a ligand-independent conjugation approach.
Founders & leadership
DP
David PerrinCo-Founder & Scientific Advisor
BN
Benjamin NoichlCo-Founder & VP of Chemistry
DW
Dan WattierChief Executive Officer
TP
Tony PolverinoFractional CSO
DW
David WoodChief Financial Officer
Investors · 1
Frequently asked questions
- What does 3C Therapeutics do?
- 3C Therapeutics develops therapeutics using targeted protein degradation, centered on a proprietary modular Degrader-Antibody Conjugate (DAC) platform (TriCore) that delivers intracellular protein degraders via monoclonal antibodies. The company focuses on drug discovery for previously inaccessible targets through a ligand-independent conjugation approach.
- Who founded 3C Therapeutics?
- 3C Therapeutics was founded by David Perrin, Benjamin Noichl.
- Who are 3C Therapeutics's investors?
- 3C Therapeutics's investors include Innovation UBC.